An investor is suing the biopharmaceutical company Geron Corp., its officers, and executive leadership for alleged violations of federal securities laws.
Lead plaintiff Reza Dabestani is bringing a proposed federal securities class action, claiming he purchased Geron common stock at artificially inflated prices during a proposed class period between June 7, 2024, and Feb. 25, 2025, and was “damaged upon the revelation of the defendants’ fraud,” according to his complaint filed Thursday in the US District Court for the Northern District of California.
The defendants “provided investors with material information” concerning expectations for the launch and growth potential of Rytelo, ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.